UniQure has submitted its closely watched Huntington’s disease gene therapy for UK approval, a move the company calls symbolic as the treatment faces an uncertain regulatory path in the United States. The submission, announced Tuesday, targets a first-ever authorization for the experimental therapy, which aims to address the root genetic cause of the fatal neurodegenerative disorder.
No clinical data were disclosed in the submission announcement. Earlier trials have shown the therapy can reduce levels of the toxic huntingtin protein, though efficacy and safety data remain under scrutiny. Analysts note that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has shown willingness to approve innovative gene therapies with smaller datasets than the FDA typically requires.
Regulatory timelines remain unclear. UniQure has not provided a PDUFA date or expected review period. The company’s U.S. application is stalled after the FDA placed a clinical hold on the program last year due to manufacturing concerns, leaving European approval as the therapy’s most viable near-term path to market.
The news sent UniQure shares up 8% in premarket trading, reflecting investor optimism that UK approval could unlock a small but symbolic market. Huntington’s disease affects approximately 8,000 people in the UK, with no disease-modifying therapies currently approved. Competitors like Roche and Ionis are also developing gene-silencing approaches, but none have reached regulatory submission.
Patient advocacy groups welcomed the filing but stressed the need for rigorous safety monitoring. If approved, the therapy would offer the first targeted treatment for Huntington’s, though questions about long-term durability and side effect profiles persist. The company expects a decision within 12 to 18 months.